Satsuma Pharmaceuticals, Inc. (STSA) |
| 1.1 0 (0%) 06-07 16:00 |
| Open: | 1.11 |
| High: | 1.1 |
| Low: | 1.1 |
| Volume: | 1,826,389 |
| Market Cap: | 36(M) |
| PE Ratio: | -0.55 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 8.08 |
| 52w Low: | 0.59 |
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Tue, 24 Feb 2026
The Commercial Launch of Atzumi: A Pivotal Moment for Satsuma's Legacy Shareholders () - aktiencheck.de
Wed, 05 Nov 2025
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache - PR Newswire
Thu, 19 Jun 2025
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting - PR Newswire
Wed, 21 May 2025
Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire
Wed, 30 Apr 2025
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine - PR Newswire
Wed, 11 Sep 2024
Rivus Pharmaceuticals Strengthens Executive Team and Board with Appointments of Tom O'Neil as Chief Financial Officer and Erin Lavelle as Director - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
